Ray Therapeutics Inc

Ray Therapeutics Inc. (RayTx) is a privately held biotechnology company based in Berkeley, California. The company employs 8 people and has generated $2.5 million in revenue. RayTx is focused on developing a novel precision optogenetic therapy for vision restoration. RayTx's technology centers around a proprietary ChRown optogenetic protein designed to restore high levels of visual acuity, contrast sensitivity, and visual field in patients suffering from various forms of retinal blindness. Their lead asset, RTx-015, aims to address the significant unmet medical need for individuals with conditions like advanced age-related macular degeneration and retinitis pigmentosa, regardless of the underlying genetic cause. To ensure the success of their clinical development, RayTx has partnered with a leading AAV gene therapy manufacturer, leveraging their expertise in commercial manufacturing processes and analytics. This collaboration aims to minimize risks associated with clinical trials. For more information about Ray Therapeutics Inc. and their groundbreaking vision restoration therapy, visit their website at raytherapeutics.com.